Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 2.59
MYOS's Cash to Debt is ranked higher than
51% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.35 vs. MYOS: 2.59 )
Ranked among companies with meaningful Cash to Debt only.
MYOS' s 10-Year Cash to Debt Range
Min: 0.13  Med: 10000.00 Max: No Debt
Current: 2.59
Equity to Asset 0.81
MYOS's Equity to Asset is ranked higher than
78% of the 575 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. MYOS: 0.81 )
Ranked among companies with meaningful Equity to Asset only.
MYOS' s 10-Year Equity to Asset Range
Min: 0.17  Med: 0.88 Max: 0.96
Current: 0.81
0.17
0.96
F-Score: 3
Z-Score: -4.06
M-Score: -0.71
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -3038.83
MYOS's Operating margin (%) is ranked lower than
97% of the 669 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.92 vs. MYOS: -3038.83 )
Ranked among companies with meaningful Operating margin (%) only.
MYOS' s 10-Year Operating margin (%) Range
Min: -4642.42  Med: -244.25 Max: -128.6
Current: -3038.83
-4642.42
-128.6
Net-margin (%) -2681.07
MYOS's Net-margin (%) is ranked lower than
97% of the 671 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.96 vs. MYOS: -2681.07 )
Ranked among companies with meaningful Net-margin (%) only.
MYOS' s 10-Year Net-margin (%) Range
Min: -5653.54  Med: -281.28 Max: -128.48
Current: -2681.07
-5653.54
-128.48
ROE (%) -89.78
MYOS's ROE (%) is ranked lower than
93% of the 699 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.43 vs. MYOS: -89.78 )
Ranked among companies with meaningful ROE (%) only.
MYOS' s 10-Year ROE (%) Range
Min: -2665.24  Med: -117.33 Max: -88.51
Current: -89.78
-2665.24
-88.51
ROA (%) -78.00
MYOS's ROA (%) is ranked lower than
95% of the 718 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.50 vs. MYOS: -78.00 )
Ranked among companies with meaningful ROA (%) only.
MYOS' s 10-Year ROA (%) Range
Min: -2600  Med: -83.05 Max: -45
Current: -78
-2600
-45
ROC (Joel Greenblatt) (%) -199.80
MYOS's ROC (Joel Greenblatt) (%) is ranked lower than
85% of the 714 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.24 vs. MYOS: -199.80 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
MYOS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -371466.67  Med: -1386.73 Max: -251.9
Current: -199.8
-371466.67
-251.9
Revenue Growth (3Y)(%) 144.50
MYOS's Revenue Growth (3Y)(%) is ranked higher than
99% of the 548 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. MYOS: 144.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
MYOS' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: 0.00 Max: 144.5
Current: 144.5
0
144.5
EBITDA Growth (3Y)(%) -26.80
MYOS's EBITDA Growth (3Y)(%) is ranked lower than
86% of the 494 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.30 vs. MYOS: -26.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
MYOS' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -37  Med: 245.50 Max: 508.7
Current: -26.8
-37
508.7
EPS Growth (3Y)(%) -30.00
MYOS's EPS Growth (3Y)(%) is ranked lower than
84% of the 455 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. MYOS: -30.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
MYOS' s 10-Year EPS Growth (3Y)(%) Range
Min: -37  Med: 276.20 Max: 510
Current: -30
-37
510
» MYOS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with MYOS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 0.92
MYOS's P/B is ranked higher than
89% of the 639 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.05 vs. MYOS: 0.92 )
Ranked among companies with meaningful P/B only.
MYOS' s 10-Year P/B Range
Min: 0.92  Med: 4.35 Max: 16.26
Current: 0.92
0.92
16.26
P/S 22.86
MYOS's P/S is ranked lower than
93% of the 664 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.08 vs. MYOS: 22.86 )
Ranked among companies with meaningful P/S only.
MYOS' s 10-Year P/S Range
Min: 4.13  Med: 11.69 Max: 500
Current: 22.86
4.13
500
Current Ratio 3.88
MYOS's Current Ratio is ranked higher than
71% of the 619 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.29 vs. MYOS: 3.88 )
Ranked among companies with meaningful Current Ratio only.
MYOS' s 10-Year Current Ratio Range
Min: 0.03  Med: 4.60 Max: 27.24
Current: 3.88
0.03
27.24
Quick Ratio 2.17
MYOS's Quick Ratio is ranked higher than
61% of the 618 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.68 vs. MYOS: 2.17 )
Ranked among companies with meaningful Quick Ratio only.
MYOS' s 10-Year Quick Ratio Range
Min: 0.03  Med: 2.88 Max: 26.31
Current: 2.17
0.03
26.31
Days Inventory 1.00
MYOS's Days Inventory is ranked higher than
99% of the 634 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 111.99 vs. MYOS: 1.00 )
Ranked among companies with meaningful Days Inventory only.
MYOS' s 10-Year Days Inventory Range
Min: 43.32  Med: 204.43 Max: 1919.9
Current: 1
43.32
1919.9
Days Sales Outstanding 1.00
MYOS's Days Sales Outstanding is ranked higher than
99% of the 601 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 70.80 vs. MYOS: 1.00 )
Ranked among companies with meaningful Days Sales Outstanding only.
MYOS' s 10-Year Days Sales Outstanding Range
Min: 66.36  Med: 75.90 Max: 107.22
Current: 1
66.36
107.22

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 1.49
MYOS's Price/Net Current Asset Value is ranked higher than
94% of the 384 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.25 vs. MYOS: 1.49 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
MYOS' s 10-Year Price/Net Current Asset Value Range
Min: 3.37  Med: 6.45 Max: 80.17
Current: 1.49
3.37
80.17
Price/Tangible Book 1.38
MYOS's Price/Tangible Book is ranked higher than
82% of the 590 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.77 vs. MYOS: 1.38 )
Ranked among companies with meaningful Price/Tangible Book only.
MYOS' s 10-Year Price/Tangible Book Range
Min: 3.11  Med: 6.20 Max: 80.17
Current: 1.38
3.11
80.17
Price/Median PS Value 2.00
MYOS's Price/Median PS Value is ranked lower than
77% of the 597 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.26 vs. MYOS: 2.00 )
Ranked among companies with meaningful Price/Median PS Value only.
MYOS' s 10-Year Price/Median PS Value Range
Min: 0.44  Med: 1.14 Max: 34.78
Current: 2
0.44
34.78
Earnings Yield (Greenblatt) (%) -138.90
MYOS's Earnings Yield (Greenblatt) (%) is ranked lower than
100% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. MYOS: -138.90 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MYOS' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -152.71  Med: 181.10 Max: 74436.8
Current: -138.9
-152.71
74436.8

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
MYOS Corp was incorporated in the State of Nevada on April 11, 2007. The Company is engaged in the discovery, development and commercialization of nutritional supplements, functional foods, therapeutic products and other technologies aimed at maintaining or improving the health and performance of muscle tissue. In February 2011, the Company acquired its platform dietary supplement product called MYO-T12. Its trademark includes FORTETROPIN. Its competition includes numerous nutritional supplement companies that are fragmented in terms of geographic market coverage, distribution channels and product categories.
» More Articles for MYOS

Headlines

Articles On GuruFocus.com
MYOS Corporation to Host Conference Call to Discuss Management Highlights Aug 14 2015 
MYOS Corporation Launches Optimized Re Muscle Health(TM) Website and HealthTrac App Jul 22 2015 
MYOS Corporation's Preclinical Study of Fortetropin's(TM) Mechanism of Action Demonstrate Regulatory Jan 22 2015 
MYOS Corporation to Present at the Eighth Annual OneMedForum Conference on January 13, 2015 Jan 07 2015 
MYOS Corporation Announces $1.81 Million Registered Direct Offering Nov 18 2014 
MYOS Corporation to Announce Third Quarter 2014 Financial Results and Host Conference Call on Novemb Nov 11 2014 
MYOS Corporation Announces Positive Safety Data Demonstrating Fortetropin's(TM) Lack of Adverse Effe Nov 04 2014 
MYOS Corporation Announces Statistically Significant Top-Line Clinical Data Demonstrating Fortetropi Oct 30 2014 
MYOS Corporation to Present Positive Clinical Data at 55th Annual Conference of the American College Oct 15 2014 

More From Other Websites
MYOS CORP Financials Aug 27 2015
MYOS CORP Files SEC form 8-K, Change in Directors or Principal Officers Aug 20 2015
10-Q for MYOS Corp. Aug 16 2015
MYOS CORP Files SEC form 10-Q, Quarterly Report Aug 14 2015
MYOS Corporation to Host Conference Call to Discuss Management Highlights Aug 14 2015
MYOS Corporation to Host Conference Call to Discuss Management Highlights Aug 14 2015
MYOS Corporation Launches Optimized Re Muscle Health(TM) Website and HealthTrac App Jul 22 2015
MYOS Corporation Launches Optimized Re Muscle Health(TM) Website and HealthTrac App Jul 22 2015
MYOS Corporation Issues Letter to Shareholders Highlighting Key Accomplishments Jun 27 2015
MYOS Corporation Issues Letter to Shareholders Highlighting Key Accomplishments Jun 24 2015
MYOS Corporation Publishes Research Article on the Impact of Fertility on the Chicken Egg Yolk... Jun 11 2015
MYOS Corporation Publishes Research Article on the Impact of Fertility on the Chicken Egg Yolk... Jun 11 2015
MYOS Corporation Receives Health Canada Approval of Proprietary Ingredient Fortetropin(R) May 28 2015
MYOS Corporation Receives Health Canada Approval of Proprietary Ingredient Fortetropin(R) May 28 2015
MYOS Corporation Initiates Marketing Plan for Re Muscle Health(TM) Products May 26 2015
MYOS Corporation Initiates Marketing Plan for Re Muscle Health(TM) Products May 26 2015
MYOS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Material Modification to... May 19 2015
Astronaut Buzz Aldrin Relies on Re Muscle Health(TM) Products to Help Rebuild, Rejuvenate and... May 19 2015
Astronaut Buzz Aldrin Relies on Re Muscle Health(TM) Products to Help Rebuild, Rejuvenate and... May 19 2015
MYOS CORP Files SEC form 10-Q, Quarterly Report May 14 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK